Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

(2021) Paul Baas et al.   LANCET

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

(2021) Dean Anthony Fennell et al.   JOURNAL OF CLINICAL ONCOLOGY

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

(2021) Cornedine J de Gooijer et al.   Lancet Respiratory Medicine

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

(2020) S. Popat et al.   ANNALS OF ONCOLOGY

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

(2019) Arnaud Scherpereel et al.   LANCET ONCOLOGY

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

(2019) David B. Chapel et al.   HUMAN PATHOLOGY

Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)

(2019) Morihito Okada et al.   CLINICAL CANCER RESEARCH

PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma

(2018) Josine Quispel-Janssen et al.   Journal of Thoracic Oncology

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

(2017) Michele Maio et al.   LANCET ONCOLOGY

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

(2017) Simone B. S. P. Terra et al.   OncoImmunology

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

(2015) Lee M Krug et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

(2015) Susana Cedrés et al.   PLoS One

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

(2014) Aaron Scott Mansfield et al.   Journal of Thoracic Oncology

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

(2008) Justin Stebbing et al.   LUNG CANCER